Research output: Contribution to journal › Article › peer-review
Vinod Patel, Chris Sproat, Jerry Kwok, Nikki Tanna
Original language | English |
---|---|
Journal | Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics |
Early online date | 18 Aug 2017 |
DOIs | |
Accepted/In press | 1 Aug 2017 |
E-pub ahead of print | 18 Aug 2017 |
Additional links |
Tyrosine kinase inhibitors (TKIs) are oral chemotherapy drugs used primarily to treat leukemias, renal cell carcinomas, gastrointestinal stromal tumors, and neuroendocrine tumors. Within this group, a number of drugs have already been implicated in jaw necrosis. Axitinib (Inlyta) is a novel TKI currently licensed for the treatment of renal cell carcinoma. We report the first case, to our knowledge, of jaw necrosis solely related to this medication and review the literature surrounding TKIs and their implication in osteonecrosis of the jaw.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454